TCM
KDNY

TCG Crossover Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

TCG Crossover Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-796,460
Closed -$13.9M – 25
2022
Q2 		$13.9M Sell
796,460
-85,893
-10% -$1.35M 5.92% 8
2022
Q1 		$14.4M Hold
882,353
– – 5.79% 8
2021
Q4 		$14.4M Buy
+882,353
New +$12.6M 6.74% 7

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCG Crossover Management's KDNY Position: Q3 2022 in Review

TCG Crossover Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2022, closing a stake of 796,460 shares — an estimated $13.9M sold.

TCG Crossover Management first reported a position in KDNY in Q4 2021 and held it in 3 quarters. The position peaked at $14.4M in Q1 2022. 151 funds tracked by Wall St. Rank hold KDNY as of Q3 2022.

  • TCG Crossover Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • TCG Crossover Management sold 796,460 Chinook Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $13.9M.
  • TCG Crossover Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • TCG Crossover Management's Chinook Therapeutics, Inc. Common Stock position peaked at $14.4M in Q1 2022.
  • 151 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2022.

Based on TCG Crossover Management's 13F filing for Q3 2022, filed 14 Nov 2022.